Retatrutide Price Prediction: Launch Cost
What will retatrutide cost when it hits the market -- and how to access it affordably today.
With retatrutide showing the highest weight loss of any drug in clinical trials, the question on everyone's mind is: how much will it cost? Based on industry patterns and Eli Lilly's pricing strategy, here is what experts predict.
Price Prediction Analysis
Estimated Pricing
| Scenario | Monthly Cost | Annual Cost | Rationale |
|---|---|---|---|
| Low estimate | $1,100 | $13,200 | Competitive with Zepbound |
| Mid estimate | $1,350 | $16,200 | Premium for superior efficacy |
| High estimate | $1,500 | $18,000 | Flagship pricing for best-in-class |
| Compounded (Trimi) | Contact us | Significantly less | Available now |
Pricing Factors
- Superior efficacy: 24.2% weight loss justifies premium over tirzepatide (22.5%)
- Lilly's strategy: Zepbound launched at ~$1,060 -- lower than expected; may repeat
- Competition: Semaglutide and tirzepatide create competitive pressure
- Insurance dynamics: Higher price with patient assistance vs lower list price
- Market size: 100M+ Americans with obesity represent massive potential volume
Affordable Access Now
You do not need to wait for brand-name launch. Trimi offers compounded retatrutide today, along with compounded semaglutide ($99/mo) and tirzepatide ($125/mo). Our physicians help determine if retatrutide is right for you.
Why Wait? Access Retatrutide Now
Trimi offers all three GLP-1 medications at affordable compounded pricing.
Explore OptionsMedical Disclaimer
Price predictions are estimates based on industry analysis and are not guaranteed. Retatrutide is investigational. Consult your healthcare provider.
More on retatrutide
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).